Clinical Analysis Laboratory of the Medical School of the ABC (FMABC) University Center, Santo André, Brazil.
Institute of Pharmaceutical Sciences, Federal University of São Paulo (UNIFESP), Diadema, Brazil.
Int J Exp Pathol. 2022 Jun;103(3):112-120. doi: 10.1111/iep.12444.
The creation of multigene panels for prognostic and predictive purposes allows a more accurate indication of adjuvant chemotherapy for patients with breast cancer. In a previous study, we reproduced a multigene panel of 21 genes based on the commercial Oncotype-DX method. We submitted 183 embedded specimens obtained from breast surgery on patients with locoregional disease (stages I to III) between 2005 and 2010 performed at the Hospitals of the Medical School of the ABC Foundation. When we analysed the correlations between the score of the multigene panel and the progression-free interval (PFI) in all patients, we did not find a statistically significant association. However, when we selected only the 71 samples that had amplification of at least eight non-housekeeping genes, we observed that those with scores above the 75th percentile had a significantly lower PFI (p = .0054). Samples processed with nonbuffered formaldehyde were associated with a worse quality of extracted RNA (p = .004) and a significantly higher multigene panel score (p = .021). We conclude that variations in the pre-analytical processing of specimens destined for multigene panel amplification can significantly affect the results, with a potential impact on clinical management.
为了预后和预测目的而创建多基因面板，可以更准确地指示乳腺癌患者接受辅助化疗。在之前的研究中，我们基于商业 Oncotype-DX 方法重现了一个包含 21 个基因的多基因面板。我们提交了 183 个从 2005 年至 2010 年在 ABC 基金会医学院附属医院接受局部区域疾病（I 期至 III 期）乳房手术的患者的嵌入式标本。当我们分析多基因面板的评分与所有患者无进展生存期（PFI）之间的相关性时，我们没有发现统计学上的显著关联。然而，当我们仅选择至少扩增八个非管家基因的 71 个样本时，我们观察到评分高于第 75 百分位数的样本具有明显较低的 PFI（p =.0054）。用非缓冲甲醛处理的样本与提取 RNA 的质量较差（p =.004）和多基因面板评分显著升高（p =.021）相关。我们得出结论，用于多基因面板扩增的标本的预分析处理的差异会显著影响结果，并可能对临床管理产生影响。
